ArticleBMC nutrition2025
Effects of caffeine supplementation on lipid profile and handgrip strength in cirrhotic patients: a randomized, placebo- controlled, clinical trial.
Article in BMC nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimAlthough it has been shown that coffee consumption can prevent the development of hepatic fibrosis and cirrhosis; the role of caffeine in improvement of cirrhosis, and its complications has not yet been elucidated.
methodsIn the present randomized placebo-controlled clinical trial, fifty patients with more than 6 months of cirrhosis diagnosis were recruited. Patients were randomly assigned to receive either two caffeine tablets (each 200 mg), or placebo for 8 weeks. Both participants and investigators were blinded to the randomization groups. Serum concentration of lipid profile, anthropometric measurements, handgrip strength, and dietary intakes were assessed at the baseline and the end of the intervention.
resultsIn the caffeine group, handgrip strength (4.7 ± 3.2 kg) and MELD score (-3.87 ± 3.3) were improved, significantly more than control group (0.56 ± 3.1 kg P = 0.006, -1.14 ± 4.1 P = 0.043, respectively) after adjusting for baseline values. Although triglyceride, total cholesterol and LDL-C increased in the caffeine group and decreased in the control group, no significant differences were detected in lipid profile between two groups after 8 weeks. Also, there were no significant differences in dietary intakes within and between groups (P > 0.05).
conclusionIt can be concluded that supplementation with 400 mg caffeine daily for 8 weeks in patients with cirrhosis may result in improvement of handgrip strength with no significant effect on lipid profile. Further studies with different caffeine dosages, and study duration are needed to find the optimum dosage of supplementation.
trial registrationThis trial was registered at the Iranian Registry of Clinical Trials (Registration ID: IRCT20100524004010N34) on 08/07/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.